<DOC>
	<DOCNO>NCT00098527</DOCNO>
	<brief_summary>This phase II trial study well FR901228 work treat patient refractory stomach cancer gastroesophageal junction . Drugs use chemotherapy , FR901228 , work different way stop growth tumor cell , either kill cell stop dividing . FR901228 may also stop growth tumor cell block enzyme need growth .</brief_summary>
	<brief_title>FR901228 Treating Patients With Refractory Stomach Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine radiographic response rate ( complete response partial response ) patient refractory adenocarcinoma stomach gastroesophageal junction treat FR901228 ( depsipeptide ) . SECONDARY OBJECTIVES : I . Determine median time progression progression-free survival patient treated drug . II . Determine grade 3 4 toxic effect drug patient . OUTLINE : This open-label , multicenter study . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 13-20 patient accrue study within 6.5-10 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma stomach gastroesophageal junction Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Refractory* least 1 , 3 , follow firstline agent : Fluoropyrimidine ( e.g. , capecitabine fluorouracil ) Taxane ( e.g. , paclitaxel docetaxel ) Platinum ( e.g. , carboplatin , cisplatin , oxaliplatin ) No know active brain metastasis Treated brain metastasis allow provided metastasis stable steroid ≥ 30 day Performance status ECOG 02 Performance status Karnofsky 60100 % At least 3 month WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) Creatinine clearance ≥ 50 mL/min No congestive heart failure No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No ventricular arrhythmia require medication No angioplasty vascular stenting within past 3 month No unstable angina No leave ventricular hypertrophy EKG No known history serious ventricular arrhythmia ( e.g. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) QTc &lt; 500 msec LVEF &gt; 40 % MUGA echocardiogram No significant cardiac disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Potassium ≥ 4.0 mmol/L ( stable level change supplementation within past 2 week ) Magnesium ≥ 2.0 mg/dL ( stable level change supplementation within past 2 week ) No history allergic reaction attribute compound similar chemical biologic composition study drug No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness Prior biological agent allow No concurrent prophylactic filgrastim ( GCSF ) No concurrent biologic therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy More 4 week since prior radiotherapy recover No concurrent radiotherapy Prior target agent allow No prior concurrent cytotoxic agents No concurrent investigational agent No concurrent anticancer therapy No concurrent medication cause QTc prolongation No concurrent potassium supplementation &gt; 40 mg/day magnesium supplementation &gt; 1 g/week No concurrent hydrochlorothiazide No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>